title: Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients.
abstract: BACKGROUND
  Population Helicobacter pylori screening and treatment has been advocated as a means of reducing mortality from gastric cancer. The optimum Helicobacter pylori eradication therapy to use in this setting is uncertain.
  
  
  OBJECTIVE
  To compare efficacy of seven days of omeprazole, clarithromycin and either metronidazole, or amoxycillin in Helicobacter pylori positive subjects detected by population screening.
  
  
  METHODS
  Helicobacter pylori positive patients from the placebo group of a population screening and treatment trial were invited to take part in the investigation.
  
  
  METHODS
  Patients were randomised to receive either omeprazole, clarithromycin and metronidazole or omeprazole, clarithromycin and amoxycillin, and Helicobacter pylori eradication was verified with a 13C-urea breath test at least four weeks after completion of therapy.
  
  
  RESULTS
  A total of 221 patients took part in the study and 210 completed the protocol. Treatment was successful in 93/111 [84%) patients allocated to omeprazole, clarithromycin and metronidazole and in 96/110 (87%) allocated to omeprazole, clarithromycin and amoxycillin in an intention-to-treat analysis (p=0.46). Per protocol eradication rates were 93/107 (87%) in the metronidazole, and 96/103 (93%) amoxycillin group (p=0.129).
  
  
  CONCLUSIONS
  There was no significant difference between the two regimens. The eradication rates achieved are comparable with previous studies in both dyspepsia and peptic ulcer patients.
authors.affiliation: Centre for Digestive Diseases, The General Infirmary at Leeds, UK. pandsnev@globalnet.co.uk
authors.forename: P M
authors.initials: PM
authors.lastname: Neville
authors.forename: S
authors.initials: S
authors.lastname: Barrowclough
authors.forename: W
authors.initials: W
authors.lastname: Crocombe
authors.forename: A T
authors.initials: AT
authors.lastname: Axon
authors.forename: M
authors.initials: M
authors.lastname: Wrangstadh
authors.forename: P
authors.initials: P
authors.lastname: Moayyedi
mesh_terms: D000328:Adult; D000658:Amoxicillin / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D016015:Logistic Models; D008297:Male; D008403:Mass Screening; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D011336:Probability; D012016:Reference Values; D016896:Treatment Outcome
chemical_list: D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole